Biodexa Pharmaceuticals (BDRX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biodexa Pharmaceuticals PLC has announced the departure of Dmitry Zamoryakhin, its Chief Scientific Officer and Chief Medical Officer, as of July 4, 2024. The company has engaged an interim consultant to take over the Chief Medical Officer role while they search for a permanent replacement. This corporate update is set to impact the company’s registration statements and investor considerations.
For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.